Arena Pharmaceuticals Inc (ARNA)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Arena Pharmaceuticals Inc (ARNA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014343
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:61
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Arena Pharmaceuticals Inc (Arena) is a biopharmaceutical company which discovers, develops and commercializes small molecule drugs in multiple therapy areas. Its pipeline portfolio encompasses etrasimod for multiple inflammatory indications; ralinepag for the treatment of pulmonary arterial hypertension (PAH); and APD371 for pain associated with Crohn’s disease. The company also has partnered development programs including Belviq (lorcaserin HCl) for chronic weight management for adults with obesity; nelotanserin for patients with Lewy body dementia (LBD) suffering from visual hallucinations. The company has collaborations with Eisai, Axovant Sciences and Boehringer Ingelheim. It has a manufacturing facility in Zofingen, Switzerland. Arena is headquartered in San Diego, California, the US.

Arena Pharmaceuticals Inc (ARNA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Boehringer Ingelheim Enters into Research Agreement with Arena Pharma 12
Arena Pharma Enters into Co-Development and Marketing Agreement with Roivant 13
Abic Marketing Enters into Agreement with Arena Pharma 14
Eisai Amends its Co-Marketing Agreement with Arena Pharma for Belviq 15
Arena Pharma Enters Into Co-Marketing Agreement With CY Biotech For Lorcaserin 17
Arena Pharma Enters Into Co-Marketing Agreement With Ildong Pharma For Belviq 18
Arena Pharma Expands Co-Marketing Agreement With Eisai For Lorcaserin 19
Licensing Agreements 20
Arena Pharma Enters Into Licensing And Co-Development Agreement With Ildong Pharma For Temanogrel 20
Suzhou Connect Biopharma Enters Into Licensing Agreement With Arena Pharma For Inflammatory Compounds 22
Equity Offering 23
Arena Pharma Raises USD172.5 Million in Public Offering of Shares 23
Arena Pharma Raises USD79.4 Million in Public Offering of Shares 25
Arena Pharma to Raise Funds through Public Offering of Shares 27
Arena Pharma Completes Public Offering Of Common Stock For US$70 Million 28
Arena Pharma Completes Private Placement Of Common Stock For US$16.5 Million 29
Arena Pharma Completes Private Placement Of Series D Preferred Stock For US$16.5 Million 31
Arena Pharma Announces Private Placement Of Common Stock For US$50 Million 33
Arena Pharma Completes Registered Direct Offering Of Common Stock For US$18 Million 34
Arena Pharma Completes Registered Direct Offering Of Series C Preferred Stock For US$18 Million 36
Arena Pharmaceuticals Inc – Key Competitors 38
Arena Pharmaceuticals Inc – Key Employees 39
Arena Pharmaceuticals Inc – Locations And Subsidiaries 40
Head Office 40
Other Locations & Subsidiaries 40
Recent Developments 41
Strategy And Business Planning 41
Sep 01, 2016: Arena Pharmaceutics Announces Formation of Beacon Discovery 41
Financial Announcements 42
Nov 07, 2017: Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2017 Financial Results 42
Aug 07, 2017: Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2017 Financial Results 43
May 09, 2017: Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2017 Financial Results 45
Mar 14, 2017: Arena Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2016 Financial Results 46
Nov 07, 2016: Arena Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Corporate Update 48
Aug 08, 2016: Arena Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update 49
May 09, 2016: Arena Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Corporate Update 50
Feb 29, 2016: Arena Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update 51
Corporate Communications 53
Jun 14, 2017: Arena Pharmaceuticals Appoints Jennifer Jarrett to Board of Directors 53
Mar 20, 2017: Arena Pharmaceuticals Appoints Dr. Preston Klassen, M.D., M.H.S. as Executive Vice President, Research and Development and Chief Medical Officer 54
Feb 14, 2017: Arena Pharmaceuticals Appoints Three New Members to Board of Directors 55
Jun 15, 2016: Arena Pharmaceuticals Announces Appointment of Kevin R. Lind as Chief Financial Officer 56
May 09, 2016: Arena Pharmaceuticals Announces Appointment of Amit D. Munshi as President and Chief Executive Officer 57
Product News 58
10/11/2016: Arena Pharmaceuticals Announces Acceptance of Late Breaking Etrasimod Abstract at the United European Gastroenterology Week (UEGW) Meeting 58
06/13/2016: Arena Pharmaceuticals Announces USAN Approval of Nonproprietary Name “Etrasimod” for its Drug Candidate APD334 59
Other Significant Developments 60
Jun 30, 2016: Arena Pharmaceuticals Announces Shift to Focus on Proprietary Clinical Stage Pipeline 60
Appendix 61
Methodology 61
About GlobalData 61
Contact Us 61
Disclaimer 61

List of Tables
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Arena Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Boehringer Ingelheim Enters into Research Agreement with Arena Pharma 12
Arena Pharma Enters into Co-Development and Marketing Agreement with Roivant 13
Abic Marketing Enters into Agreement with Arena Pharma 14
Eisai Amends its Co-Marketing Agreement with Arena Pharma for Belviq 15
Arena Pharma Enters Into Co-Marketing Agreement With CY Biotech For Lorcaserin 17
Arena Pharma Enters Into Co-Marketing Agreement With Ildong Pharma For Belviq 18
Arena Pharma Expands Co-Marketing Agreement With Eisai For Lorcaserin 19
Arena Pharma Enters Into Licensing And Co-Development Agreement With Ildong Pharma For Temanogrel 20
Suzhou Connect Biopharma Enters Into Licensing Agreement With Arena Pharma For Inflammatory Compounds 22
Arena Pharma Raises USD172.5 Million in Public Offering of Shares 23
Arena Pharma Raises USD79.4 Million in Public Offering of Shares 25
Arena Pharma to Raise Funds through Public Offering of Shares 27
Arena Pharma Completes Public Offering Of Common Stock For US$70 Million 28
Arena Pharma Completes Private Placement Of Common Stock For US$16.5 Million 29
Arena Pharma Completes Private Placement Of Series D Preferred Stock For US$16.5 Million 31
Arena Pharma Announces Private Placement Of Common Stock For US$50 Million 33
Arena Pharma Completes Registered Direct Offering Of Common Stock For US$18 Million 34
Arena Pharma Completes Registered Direct Offering Of Series C Preferred Stock For US$18 Million 36
Arena Pharmaceuticals Inc, Key Competitors 38
Arena Pharmaceuticals Inc, Key Employees 39
Arena Pharmaceuticals Inc, Other Locations 40
Arena Pharmaceuticals Inc, Subsidiaries 40

★海外企業調査レポート[Arena Pharmaceuticals Inc (ARNA)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Vivimed Labs Ltd (VIVIMEDLAB):製薬・医療:M&Aディール及び事業提携情報
    Summary Vivimed Labs Ltd (Vivimed) is a supplier of niche molecules and formulations to healthcare, pharmaceuticals and specialty chemicals customers across the world. The company provides active pharmaceutical ingredients (APIs), finished dosage formulations, and specialty chemicals. It manufacture …
  • Palfinger AG (PAL):企業の財務・戦略的SWOT分析
    Palfinger AG (PAL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Alimentation Couche-Tard Inc (ATD.B):石油・ガス:M&Aディール及び事業提携情報
    Summary Alimentation Couche-Tard Inc (Couche-Tard) is a retail company that operates an extensive network of convenience stores. The company principally offers food and non-food items as well as transportation fuels. Couche-Tard products include tobacco, alcohol, grocery items, candy, snacks and var …
  • Canon Marketing Japan Inc (8060):企業の財務・戦略的SWOT分析
    Canon Marketing Japan Inc (8060) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Cobb Electric Membership Corporation:企業の戦略的SWOT分析
    Cobb Electric Membership Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and majo …
  • Novant Health Inc:企業の戦略的SWOT分析
    Novant Health Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Main Line Health System:企業の戦略的SWOT分析
    Main Line Health System - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • ContourGlobal LP-エネルギー分野:企業M&A・提携分析
    Summary ContourGlobal L.P. (CGLP) is an energy company that owns and operates of power generation assets. It develops, acquires and operates electric power and district heating businesses. The company develops and operates large central power plants in emerging markets to support the growth of the n …
  • Alfa Group Consortium:企業の戦略的SWOT分析
    Alfa Group Consortium - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Prothena Corp Plc (PRTA)-医療機器分野:企業M&A・提携分析
    Summary Prothena Corp Plc (Prothena) is a biotechnology company that discovers, develops and markets novel antibodies that are indicated for the treatment of diseases associated with amyloid or cell adhesion. The company develops monoclonal antibodies directed specifically at disease-causing protein …
  • Kier Group plc:企業のM&A・事業提携・投資動向
    Kier Group plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Kier Group plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • Ulthera Inc:医療機器:M&Aディール及び事業提携情報
    Summary Ulthera Inc (Ulthera), a subsidiary of Merz Pharma GmbH & Co KgaA is a medical device company that develops and commercializes technologies for aesthetic and medical applications by using its therapeutic ultrasound platform technologies. The company’s therapeutic ultrasound platform technolo …
  • Foundation Radiology Group PC:製薬・医療:M&Aディール及び事業提携情報
    Summary Foundation Radiology Group PC (FRG) is a provider of radiology solutions. The company offers radiological services in areas of pediatric, neurology, mammography, musculoskeletal, PET and CT, cardiac CT and interventional radiology. It offers imaging solutions for the radiologists and systems …
  • Ontario Power Generation Inc:電力:M&Aディール及び事業提携情報
    Summary Ontario Power Generation Inc (OPG) is an electric utility. It generates and sells energy. The company produces power from nuclear, hydro, and thermal sources. OPG has long-term lease arrangement and related agreements with Bruce Power related to the Bruce nuclear generating stations. It also …
  • CKE Restaurants Holdings Inc.:企業の戦略・SWOT・財務分析
    CKE Restaurants Holdings Inc. - Strategy, SWOT and Corporate Finance Report Summary CKE Restaurants Holdings Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Intermountain Rural Electric Association:企業の発電所・SWOT分析2018
    Intermountain Rural Electric Association - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, informa …
  • Arrowhead Pharmaceuticals Inc (ARWR):製薬・医療:M&Aディール及び事業提携情報
    Summary Arrowhead Pharmaceuticals Inc (Arrowhead), formerly Arrowhead Research Corp, is a pharmaceutical company that develops and markets medicinal products. The company develops pipeline drugs that are being developed to treat chronic hepatitis B virus infection for the treatment of liver disease, …
  • Irkut Corporation (IRKT):企業の財務・戦略的SWOT分析
    Irkut Corporation (IRKT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Expro Holdings UK 3 Ltd:企業の戦略的SWOT分析
    Expro Holdings UK 3 Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Kellstrom Defense Aerospace, Inc.:企業の戦略・SWOT・財務情報
    Kellstrom Defense Aerospace, Inc. - Strategy, SWOT and Corporate Finance Report Summary Kellstrom Defense Aerospace, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆